# Julien Edeline

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/julien-edeline/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,412 |
| Field | Hepatocellular Carcinoma Treatment and Prognosis |
| h-index | 52 |
| i10-index | 152 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5069522018 |
| ORCID iD | https://orcid.org/0000-0002-8289-7741 |
| Works | 409 |

## Researcher papers

- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)
- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-selective-internal-radiotherapy-with-yttrium-90-resin/)
- [Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/biliary-tract-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)

## Researcher topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.